Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of NiCord versus unmanipulated umbilical cord blood transplantation
2016-000704-28Phase 3Completed
- Sponsor
- Gamida Cell
- Start
- May 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of omidubicel in hematopoietic malignancies and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Gamida Cell. Primary endpoint: Time to neutrophil engraftment following transplantation. Started May 2016; status: completed.
02
Drugs
omidubicel
03
Conditions
hematopoietic malignanciesacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-000704-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000704-28.